Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Lucia Masarova

Lucia Masarova

MD
The University of Texas MD Anderson Cancer Center
Splicing mutations in post-ET/post-PV myelofibrosis 2:13
Splicing mutations in post-ET/post-PV myelofibrosis
Lucia Masarova • 9 Dec 2023
What’s on the horizon for the treatment of MPNs? 1:19
What’s on the horizon for the treatment of MPNs?
Lucia Masarova • 9 Dec 2023
Estimating transfusion-related medical costs & time burden in patients with MF in SIMPLIFY-1 3:17
Estimating transfusion-related medical costs & time burden in patients with MF in SIMPLIFY-1
Lucia Masarova • 9 Dec 2023
Add-on therapy with CK0804 for patients with MF who exhibit a suboptimal response to ruxolitinib 2:08
Add-on therapy with CK0804 for patients with MF who exhibit a suboptimal response to ruxolitinib
Lucia Masarova • 9 Dec 2023
Cladribine-based chemotherapy for patients with secondary AML arising after MPNs 3:18
Cladribine-based chemotherapy for patients with secondary AML arising after MPNs
Lucia Masarova • 9 Dec 2023
SURPASS ET: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia 1:28
SURPASS ET: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia
Lucia Masarova • 9 Sep 2023
The impact of anemia and transfusion dependence on patient QoL in myelofibrosis 1:30
The impact of anemia and transfusion dependence on patient QoL in myelofibrosis
Lucia Masarova • 9 Sep 2023
Indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis 1:28
Indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
Lucia Masarova • 9 Sep 2023
MAIC of momelotinib versus fedratinib safety in myelofibrosis 1:52
MAIC of momelotinib versus fedratinib safety in myelofibrosis
Lucia Masarova • 9 Sep 2023
Current and emerging therapies for polycythemia vera 3:20
Current and emerging therapies for polycythemia vera
Lucia Masarova • 9 Sep 2023
The role of NGS in improving diagnosis in MPNs 1:47
The role of NGS in improving diagnosis in MPNs
Lucia Masarova • 9 Sep 2023
LIMBER-TREG108: CK0804 add-on therapy in patients with MF with suboptimal response to ruxolitinib 1:47
LIMBER-TREG108: CK0804 add-on therapy in patients with MF with suboptimal response to ruxolitinib
Lucia Masarova • 8 Jun 2023
Indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis 1:16
Indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
Lucia Masarova • 8 Jun 2023
Safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis 3:20
Safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
Lucia Masarova • 8 Jun 2023
EXCEED-ET: ropeginterferon alfa-2b in adults with essential thrombocythemia 1:24
EXCEED-ET: ropeginterferon alfa-2b in adults with essential thrombocythemia
Lucia Masarova • 8 Jun 2023
The importance of symptom management in MPNs 1:52
The importance of symptom management in MPNs
Lucia Masarova • 8 Jun 2023
The content of VJHemOnc is intended for healthcare professionals